UPDATE: SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease
Spherix Incorporated (NASDAQ: SPEX) – today announced that one of its drug candidates, SPX-106T, arrested development and reduced atherosclerotic plaque area in the aortic arch, thoracic aorta and sinus of Valsalva in mice genetically predisposed to cardiovascular disease. Atherosclerosis can lead to myocardial infarction (MI) and stroke. Each year, about 770,000 people in the United States experience their first MI, and about one-third of these events are fatal.(1-3)
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.